Trials / Completed
CompletedNCT06070610
A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood
The Effect of Multiple Oral Doses of BI 1015550 on the Pharmacokinetics of Nintedanib and Pirfenidone Administered Single Dose to Healthy Male Subjects (Open-label, Two-period, Fixed-sequence Crossover Trial)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this trial is to investigate the induction effect of multiple oral doses of BI 1015550 on the pharmacokinetics of nintedanib or pirfenidone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1015550 | BI 1015550 |
| DRUG | Nintedanib | Soft capsules |
| DRUG | Pirfenidone | Film-coated tablets |
Timeline
- Start date
- 2023-11-08
- Primary completion
- 2023-12-14
- Completion
- 2023-12-14
- First posted
- 2023-10-06
- Last updated
- 2025-12-02
- Results posted
- 2025-12-02
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT06070610. Inclusion in this directory is not an endorsement.